Christelle Chacar, Oncology Medical Director; solid tumors at Servier Pharmaceuticals, shared on LinkedIn:
“I’m honored and excited to step into my new role leading the Neuro-Oncology Medical Strategy team at Servier.
Over the past 3 years, I have had the privilege of contributing to the successful launch of vorasidenib for adults with mIDH glioma, an important and unique milestone in neuro-oncology.
As we now expand our focus to include pediatric glioma, I’m incredibly excited about the opportunities and challenges ahead.
Grateful for the journey so far, the talented colleagues I get to work alongside, and the opportunity to lead a team committed to advancing science and making a meaningful difference for patients with low-grade glioma.”
Other articles featuring Christelle Chacar and Servier on OncoDaily.